Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Anadys Pharmaceticals, Inc. (“Anadys” or the “Company”) (Nasdaq: ANDS) relating to the proposed acquisition Roche Holding AG. (“Roche”).

Under the terms of the transaction Anadys shareholders would receive $3.70 in cash for each share of Anadys stock they own. The investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Anadys for not acting in the Anadys shareholders' best interests in connection with the sale process to Roche. The transaction may undervalue the Company as an analyst has set a price target of $4.00 for Anadys stock.

If you own shares of Anadys stock and wish to discuss the legal ramifications of the proposed transaction, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at investorrelations@brodsky-smith.com, visiting http://brodsky-smith.com/345-ands-anadys-pharmaceuticals-inc.html, or by calling toll free 877-LEGAL-90.

Copyright Business Wire 2010

If you liked this article you might like

7 Stocks Hitting New 52-Week Highs

7 Stocks Hitting New 52-Week Highs

Roche's All-Oral Hep C Therapy Could Be First, Not Best, to Reach Market

Roche's All-Oral Hep C Therapy Could Be First, Not Best, to Reach Market

Roche-Anadys Hookup Could Spark More Hep C Acquisitions

Roche-Anadys Hookup Could Spark More Hep C Acquisitions

Anadys To Be Bought by Roche for $230M

Anadys To Be Bought by Roche for $230M

Hep C Drug Updates: Vertex and Anadys

Hep C Drug Updates: Vertex and Anadys